Engineered immune cells take on advanced liver cancer in first human trial

NCT ID NCT06676982

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called CNCT19 CAR-T cells for people with advanced liver cancer that cannot be removed by surgery or has come back after other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goals are to check safety and find the best dose, with only 12 participants enrolled so far.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CNCT19 CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced liver cancer that is hard to treat with standard methods.
What could go wrong: This is a very early phase 1 trial with only 12 people, so it is mainly checking safety and dosing. It may not show strong anti-cancer effects, and CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

First Affiliated Hospital, Medical College of Zhejiang University
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.